Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADC3680 add-on therapy in inadequately controlled asthma
2012-003966-42Phase 2Completed
- Sponsor
- Pulmagen Therapeutics
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GB001 in asthma (4 arms), sponsored by Pulmagen Therapeutics. Primary endpoint: Change in lung function (FEV1). Started Feb 2013; status: completed.
02
Drugs
GB001
03
Conditions
asthma
Beyond the preview
Go deeper on 2012-003966-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003966-42.